Here is an overview of the research impact dimensions based on the provided document:

Domains of Research Impact:

The study on secukinumab's efficacy for treating Psoriatic Arthritis (PsA) touches several domains, primarily health and clinical research. The findings directly impact healthcare through advancements in treatment protocols for autoimmune conditions. It also influences the policy domain by offering data that could guide healthcare decision-makers and the pharmaceutical industry in developing treatment guidelines for PsA patients​(Knowledge - Potential R…)​(Knowledge - Potential R…).
Duration of Research Impact:

Short-term: The clinical efficacy of secukinumab shows immediate benefits, with rapid improvements in PsA symptoms sustained over two years. This provides evidence for short-term adoption in healthcare settings​(5)​(Knowledge - Potential R…).
Long-term: Given its safety and efficacy over two years, this study forms a long-term foundation for future PsA therapies, influencing ongoing clinical practices and possibly future studies related to autoimmune treatments​(Knowledge - Potential R…).
Stakeholders of Research Impact:

Direct stakeholders: Healthcare providers, particularly rheumatologists and dermatologists, will directly benefit from the findings to improve patient outcomes. Pharmaceutical companies are also stakeholders, as they can use these findings to guide drug development and marketing​(Knowledge - Potential R…)​(5).
Indirect stakeholders: PsA patients benefit from more effective treatments, while policymakers can use these results to shape guidelines​(5)​(Knowledge - Potential R…).
Depth and Breadth of Impact:

Deep impact: The clinical trial provides robust data specific to PsA treatment, deeply influencing the field of rheumatology and potentially becoming a benchmark for future treatments​(Knowledge - Potential R…).
Broad impact: The study spans multiple clinical domains, including joint health, skin condition, and overall patient quality of life, showing broad applicability beyond just one aspect of PsA​(5) .
Scalability and Transferability:

Scalability: The results can be scaled to other populations with similar autoimmune diseases beyond PsA, particularly where biologic treatments are needed​(Knowledge - Potential R…)​(5).
Transferability: Insights from this study can be adapted for other immune-related disorders treated with biologics, showcasing high transferability across fields like dermatology and immunology​(5) .
Innovation and Disruption Potential:

The development of secukinumab as an innovative biologic therapy demonstrates significant disruption in the field of autoimmune disease treatment. It provides a new approach to managing PsA, potentially replacing older treatments that were less effective (Knowledge - Potential R…).
Sustainability and Ethical Considerations:

Sustainability: The study provides data that can sustain long-term patient management strategies, contributing to the sustainable treatment of chronic diseases like PsA​(Knowledge - Potential R…)​(Knowledge - Potential R…).
Ethical considerations: The trial was conducted according to ethical guidelines, as acknowledged in the discussion, ensuring patient safety and adherence to international research standards​(Knowledge - Potential R…)​(Knowledge - Potential R…).
Cross-disciplinary and Global Relevance:

The study’s findings are globally relevant, influencing cross-disciplinary fields such as rheumatology, dermatology, and public health. The widespread use of secukinumab can have implications for global treatment protocols for PsA and other inflammatory diseases​(Knowledge - Potential R…) .
Implementation and Usability:

The findings are highly implementable in clinical settings, given the detailed efficacy and safety data presented. Healthcare providers can easily integrate this biologic into their treatment plans for PsA (Knowledge - Potential R…).
Resilience and Adaptability:

The study demonstrates the drug’s ability to provide resilient outcomes in patients over two years, showing adaptability across different patient profiles, including those with and without prior anti-TNF therapy exposure​(Knowledge - Potential R…) .
These dimensions highlight the extensive and long-lasting impact of the research on secukinumab in clinical practice, policymaking, and patient care.